Adavosertib Explained

Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity.[1] It is being developed by AstraZeneca.[2] It is being investigated as a treatment for pancreatic cancer with a phase 1 trial (University of Michigan researchers are as of 2019 planning a phase 2 study.[3]), and ovarian cancer, in combination with another anti-cancer drug, gemcitabine, as a phase 2 trial.[4] [5] [6]

Notes and References

  1. Web site: NCI Drug Dictionary . National Cancer Institute . 17 August 2019 . en . 2 February 2011.
  2. Web site: AZD1775 AstraZeneca Open Innovation . openinnovation.astrazeneca.com . 17 August 2019 . en . 17 August 2019 . https://web.archive.org/web/20190817234728/https://openinnovation.astrazeneca.com/azd1775.html . dead .
  3. Web site: AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival . 17 August 2019 . FierceBiotech . en.
  4. Lheureux . Stephanie . Cristea . Mihaela C. . Bruce . Jeffrey P. . Garg . Swati . Cabanero . Michael . Mantia-Smaldone . Gina . Olawaiye . Alexander B. . Ellard . Susan L. . Weberpals . Johanne I. . Wahner Hendrickson . Andrea E. . Fleming . Gini F. . Welch . Stephen . Dhani . Neesha C. . Stockley . Tracy . Rath . Prisni . 2021-01-23 . Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial . Lancet . 397 . 10271 . 281–292 . 10.1016/S0140-6736(20)32554-X . 1474-547X . 33485453. 231667519 . free . 10792546 .
  5. Web site: Early Activity in Pancreatic Cancer With New Drug . www.medpagetoday.com . 17 August 2019 . en . 16 August 2019.
  6. Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, Devasia T, Al-Hawaray M, Cho CS, Nathan H, Maybaum J, Zalupski MM, Lawrence TS . 6 . Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer . Journal of Clinical Oncology . 37 . 29 . 2643–2650 . October 2019 . 31398082 . 7006846 . 10.1200/JCO.19.00730 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Adavosertib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.